H-1BSalary Explorer

Employers

Strand Therapeutics Inc. H-1B salaries

Strand Therapeutics Inc. filed 17 certified H-1B applications between May 2024 and May 2026. Half of them paid more than $105,331 a year. The typical offer was about level with the prevailing wage, the minimum the law sets for the job and place.

Median salary offered
$105,331
Middle half earn
$84,906 to $113,464
Top 10% earn over
$123,737
Certified filings
17

Every filing

Loading filings…

Pay by job title

Principal Associate Scientist of Immune Cell Engineering2$105,487–$104,265 – $106,709
Associate Scientist I, In Vivo Discovery1$79,581–$79,581 – $79,581
Associate Scientist I of Cellular Analytical Development1$79,581–$79,581 – $79,581
Associate Scientist I, Nanoparticle Process Development1$79,581–$79,581 – $79,581
Associate Scientist II, Immune Cell Engineering1$70,470–$70,470 – $70,470
Engineer II, Data Analytics & Machine Learning1$105,331–$105,331 – $105,331
Principal Associate Scientist of LNP Discovery1$113,464–$113,464 – $113,464
Principal Scientist of Immune Cell Engineering1$124,842–$124,842 – $124,842
Scientist, LNP Discovery1$122,450–$122,450 – $122,450
Scientist of LNP Discovery1$123,000–$123,000 – $123,000
Senior Associate Scientist, Analytical Operations1$103,442–$103,442 – $103,442
Senior Associate Scientist, mRNA Process Development1$107,931–$107,931 – $107,931
Senior Associate Scientist of LNP Discovery1$84,906–$84,906 – $84,906
Senior Associate Scientist of mRNA Process Development1$107,931–$107,931 – $107,931
Senior Associate Scientist, Vector Engineering1$93,538–$93,538 – $93,538
Senior Scientist, In Vivo Pharmacology “ Cell Therapies1$124,842–$124,842 – $124,842

Where they work

Bigger dots mean more filings; darker blue means higher pay.
Boston, MA17$105,331$84,906 – $113,464

By year

20243$107,931
20257$105,331
20267$84,906

By experience level

Level I5$79,581
Level II2$98,290
Level III7$107,931
Level IV2$124,842

Levels I to IV are the Labor Department's experience bands, from entry level (I) to fully competent (IV).